Amelioration of ongoing experimental autoimmune encephalomyelitis with fluoxetine

Roopa Bhat, Sidharth Mahapatra, Robert C. Axtell, Lawrence Steinman

Research output: Contribution to journalArticlepeer-review

28 Scopus citations


In patients with multiple sclerosis, the selective serotonin reuptake inhibitor, fluoxetine, resulted in less acute disease activity. We tested the immune modulating effects of fluoxetine in a mouse model of multiple sclerosis, i.e. experimental autoimmune encephalomyelitis (EAE). We show that fluoxetine delayed the onset of disease and reduced clinical paralysis in mice with established disease. Fluoxetine had abrogating effects on proliferation of immune cells and inflammatory cytokine production by both antigen-presenting cells and T cells. Specifically, in CD4 T cells, fluoxetine increased Fas-induced apoptosis. We conclude that fluoxetine possesses immune-modulating effects resulting in the amelioration of symptoms in EAE.

Original languageEnglish (US)
Pages (from-to)77-81
Number of pages5
JournalJournal of Neuroimmunology
StatePublished - Dec 15 2017


  • EAE
  • Experimental autoimmune encephalomyelitis
  • Fluoxetine
  • Multiple sclerosis
  • Neuroinflammation
  • SSRI

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Amelioration of ongoing experimental autoimmune encephalomyelitis with fluoxetine'. Together they form a unique fingerprint.

Cite this